99mTc-HFAPI SPECT/CT in Pulmonary Fibrosis

Status Recruiting

Clinical Trial Summary

This prospective study will investigate the potential usefulness of 99mTc labeled FAPI SPECT/CT in the diagnosis, treatment response assessment, and follow-up of pulmonary fibrosis.

Clinical Trial Description

Idiopathic pulmonary fibrosis refers to a specific form of chronic fibrous interstitial pneumonia that occurs spontaneously, limited to the lung, and shows features of usual interstitial pneumonia on high resolution computed tomography and histological examination. Radionuclide labeled FAPI has been developed as a new tracer for tumor and inflammatory lesions imaging. Recent studies have shown that FAPI PET/CT imaging is a promising new imaging method for pulmonary fibrosis. HFAPI is obtained by conjugating 99mTc-chelator moiety (6-hydrazinonicotinamide, HYNIC) with FAP targeting moiety. The aim of this study is to investigate the location and extent of 99mTc labeled FAPI tracer (99mTc-HFAPI) in normal and fibrotic lung tissue of patients with pulmonary fibrosis, and to explore the clinical significance of 99mTc-HFAPI SPECT/CT in the diagnosis, treatment response evaluation and follow-up of pulmonary fibrosis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05859763
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact	Yu Liu, MD
Phone	18511071577
Email	liuyu@pumch.cn
Status	Recruiting
Phase	N/A
Start date	December 12, 2021
Completion date	July 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04638517` - The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis	Phase 2
Recruiting	`NCT05299333` - Comparison of Pulmonary Telerehabilitation and Physical Activity Recommendations in Patients With Post Covid Fibrosis	N/A
Terminated	`NCT04119115` - Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT01417156` - Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)	Phase 2
Terminated	`NCT00981747` - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis	Phase 2/Phase 3
Completed	`NCT00001596` - Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome	Phase 2
Completed	`NCT00052052` - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Phase 2
Completed	`NCT01442779` - Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis	Phase 2
Completed	`NCT00366509` - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Recruiting	`NCT00001532` - Role of Genetic Factors in the Development of Lung Disease
Recruiting	`NCT04767074` - A Non-pharmacological Cough Control Therapy	N/A
Recruiting	`NCT04864990` - Dyspnea and Idiopathic Pulmonary Fibrosis
Completed	`NCT01961362` - Supplemental Oxygen in Pulmonary Fibrosis
Completed	`NCT01271842` - Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study	N/A
Completed	`NCT00650091` - Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF	Phase 3
Active, not recruiting	`NCT00258544` - Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
Enrolling by invitation	`NCT04930289` - Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
Completed	`NCT02055222` - Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Enrolling by invitation	`NCT06327360` - Illness Expectations in Pulmonary Fibrosis